Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Feb 20, 2024 (3 years ago)

Nicardipine Hydrochloride Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Impurities/Degradation Specifications: Out of specification for organic impurities

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Nicardipine Hydrochloride Injection (2.5mg/mL), US, 25mg per 10mL, 10mL Vial, Rx only, Distributed by: AuroMedics Pharma LLC 279 Princeton-Hightstown Rd. E. Windsor, NJ 08520 NDC 55150-183-10

Affected NDC 55150-0183-10

Compare with the code on your package — it is the most precise check available.

Drug: Nicardipine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Nicardipine Hydrochloride
NDC 55150-0183
25 mg/10mL Injection, Solution
Intravenous
Eugia US LLC Rx
Recalling firm
Eugia US LLC
NDC code
55150-183-10
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0390-2024 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Nicardipine recalls

See all
Class II · Moderate risk

Cardene IV

CGMP Deviations

Ongoing cGMP deviation Baxter Healthcare Corporation NDC 43066-016-10 D-0813-2026

Other recalls by Eugia US LLC

All 2024 recalls
Class III · Low risk

Lidocaine HCl Injection

Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan

Ongoing Labeling / mix-up Eugia US LLC D-0552-2026
Class II · Moderate risk

Gentamicin Injection

Failed Stability Specifications: Out of specification results for the Color Absorbance test during 12 Month sample analysis.

Ongoing Stability / shelf life Eugia US LLC NDC 55150-401-01 D-0472-2025